Skip to content

EBITDA at other companies

NeoGenomics logo
NeoGenomicsNEO
-$1.83M+81.9%
Personalis, Inc. logo
Personalis, Inc.PSNL
-$29.79M-97.2%
TransMedics Group, Inc. logo
TransMedics Group, Inc.TMDX
$25.16M-25.1%
Veracyte logo
VeracyteVCYT
$28.08M+240%
Thermo Fisher Scientific logo
Thermo Fisher ScientificTMO
Natera, Inc. logo
Natera, Inc.NTRA

Other financials

Income statement

See full
Revenue$117.7M+39.0%
Operating income$1.2M+109%
Net income$2.8M+127%
EPS (diluted)$0.05+126%

Balance sheet

See full
Cash & equivalents$78.5M-12.1%
Total debt$24.5M-19.1%
Total equity$313.5M-17.3%
Total assets$411.1M-16.0%

Cash flow

See full
Operating cash flow$4.3M+116%
CapEx$3.8M+134%
Free cash flow$514.0K+102%

Valuation

See full
Market cap$1.44B+35.7%
Enterprise value$1.38B+38.3%
P/S3.5×+0.4×

Profitability

See full
Gross margin65.5%
Operating margin-3.9%-18.3pp
Net margin-2%-19.9pp
FCF margin-0%0.0pp

Returns & leverage

See full
Return on equity-2.4%-21.9pp
Debt / equity0.1×0.0×
Current ratio3.4×-0.7×

Where this comes from

Calculated from CareDx’s reported figures.

$1.2Mebit+
$3.9MDepreciation Depletion & Amortization
=$5.1M

The official record: CareDx’s 10-Q, filed April 28, 2026, on SEC EDGAR. View the filing →

Ask your AI about CareDx's ebitda.

Connect your AI assistant and compare it to peers, right in your chat.

Connect your AI
Harbor at dusk
Claude

Questions, answered.

What is CareDx's EBITDA?
CareDx (CDNA) reported EBITDA of $5.1M in Q1 2026.
How has CareDx's EBITDA changed year-over-year?
CareDx's EBITDA increased by 152.1% year-over-year, from -$9.77M to $5.1M.
What is the long-term trend for CareDx's EBITDA?
Over 4 years (2021 to 2025), CareDx's EBITDA has grown at a -6.8% compound annual growth rate (CAGR), from -$20.93M to -$15.76M.
What does EBITDA mean?
Earnings before interest, taxes, depreciation, and amortization — EBIT plus the D&A add-back from the cash-flow statement (EBITDA = EBIT + D&A). A proxy for cash earnings that strips out financing, tax, and non-cash charges.